DUBLIN--(BUSINESS WIRE)--Jul 30, 2018--The "Global Liquid Biopsy Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The analysts forecast the global liquid biopsy market to grow at a CAGR of 34.25% during the period 2018-2022.

Liquid biopsy is also called fluid biopsy or fluid phase biopsy. It is a simple and non-invasive test to detect genetic changes in the tumor through a simple blood or urine sample. The preference toward liquid biopsy is significantly increasing over traditional tissue biopsy due to its less invasive nature and growing focus on personalized medicine in oncology diagnosis and treatment.

The latest trend gaining momentum in the market is the increasing funding or investments for liquid biopsy. Liquid biopsy gained momentum in the last few years, both as a research tool and as sophisticated diagnostics technology.

One of the major drivers for this market is the increasing incidence of cancer. According to CDC, in 2015, 1.63 million new cancer cases were reported in the US. Cancer changes the morphology of the human cells, as it leads to uncontrolled division of cells that results from a combination of both environmental and hereditary risk factors.

The report states that one of the major factors hindering the growth of this market is the limited imbursements. The reimbursement for liquid biopsy test in oncology is not guaranteed even after approval, as it is still considered as novel and an unproven technique. Lack of reimbursement and awareness about liquid biopsy can decline its adoption, which can hinder the market growth.

Companies Mentioned

BIOCEPT Exosome Diagnostics F. Hoffmann-La Roche GUARDANT HEALTH Myriad Genetics QIAGEN

Key Topics Covered:

1: Executive Summary

2: Scope Of The Report

3: Research Methodology

4: Market Landscape

5: Market Sizing

6: Five Forces Analysis

7: Market Segmentation By Technology

8: Customer Landscape

9: Regional Landscape

10: Decision Framework

11: Drivers And Challenges

12: Market Trends

13: Vendor Landscape

14: Vendor Analysis

15: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/5v8qr2/global_liquid?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005486/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:In Vitro Diagnostics

KEYWORD:

INDUSTRY KEYWORD: SURGERY HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/30/2018 10:51 AM/DISC: 07/30/2018 10:51 AM

http://www.businesswire.com/news/home/20180730005486/en